Proactif study.It was reported that death occurred.In (b)(6) 2020, the subject was enrolled into the proactif study and the treatment with therasphere was performed on the same day.Advanced, multicompartment dosimetry was performed to assess treatment dose.Pre-treatment dosimetry documented a strong uptake of y90 on tumors, dose to perfused liver was 78 gy and dose to perfused tumor was 372 gy.The type of therasphere infusion was in right hepatic artery (irrespective of origin) (segments v/vi/vii/viii).1.54 gbq of therasphere was administered to the right liver through vial 1.On (b)(6) 2020, the subject was hospitalized due to mild ascites with moderate lower limb edema.Jaundice with fever was noted and hepatic failure increased.The subject was treated with antibiotherapy and started on tazocilline iv.On (b)(6) 2021, the subject passed away.
|